Phase III SUNBEAM and RADIANCE PART B trials for Ozanimod in relapsing multiple sclerosis demonstrate superiority versus interferon-β-1a (Avonex®) in reducing annualized relapse rates and MRI brain lesions

Volker Koscielny
  • Neurodegenerative Disease Management, June 2018, Future Medicine
  • DOI: 10.2217/nmt-2018-0012
The author haven't yet claimed this publicationThe author haven't yet claimed this publication
Read Publication

http://dx.doi.org/10.2217/nmt-2018-0012

In partnership with: